US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Correction of the press release:  PExA enters into aresearch collaboration agreement with Janssen and the University of Gothenburgfor discovery of biomarkers in exhaled air

In the English version of the pressrelease from PExA AB published earlier part of the text was missing. Here follows the corrected version:  Swedish medical technology company PExA AB (“PExA”) announced that it has entered into a research collaboration agreement withJanssen Research & Development, LLC, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, and the University of Gothenburg.PExA, which focuses on the development and commercialization of a unique breath sampling technology for biomarker discovery, was recently selected Awardee of the Carcinogenic Exposure Meter

PExAenters into a research collaboration agreement with Janssen and the Universityof Gothenburg for discovery of biomarkers in exhaled air

Swedish medical technology company PExA AB(“PExA”) announced that it has entered into a research collaboration agreement withJanssen Research & Development, LLC, one of the Janssen PharmaceuticalCompanies of Johnson & Johnson, and the University of Gothenburg.biomarker discovery, was recently selected Awardee of the Carcinogenic Exposure Meter Quickfire Challenge. The Challenge was launched by Johnson & Johnson Innovation, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen in an effort to help reduce the tobacco epidemic.  As part of the collaboration, Janssen will

PExA named awardee in Carcinogenic Exposure Meter QuickFire Challenge

PExA AB (“PExA”) has been named the awardee in the “Carcinogenic Exposure Meter QuickFire Challenge”, sponsored by Johnson & Johnson Innovation - JLABS, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen Research & Development, LLC.As the awardee of the QuickFire Challenge, PExA will receive $250,000 in grant funding, mentorship and coaching from experts at Johnson & Johnson Innovation, the LCI and Janssen Research & Development, LLC, and access to the Johnson & Johnson Innovation - JLABS global entrepreneurial community.The Challenge invited innovators from across the

PExA recognized as one of the Top 20 MedTech Solution Providers in Europe 2018 by MedTech Outlook Magazine

PExA AB (“PExA”) has been recognized as one of the Top 20 MedTech Solution Providers in Europe 2018 by MedTech Outlook Magazine, an industry periodical committed to covering the trends, challenges, and solutions impacting the healthcare and medical device sectors.PExAs technology, which enable non-invasive collection of proximal biomarkers for lung diseases, was selected among its peers since its contribution to the sphere is unique and a cut above competitors and industry peers.MedTech Outlook's selection panel, comprised of physicians, healthcare executives, and the magazine's editorial

PExA receives additional order from United Kingdom

PExA AB (“PExA”) announces the sale of a PExA 2.0 system to University of Leicester, United Kingdom. Total sales price is Euro 35 000.The University of Leicester is the second university in United Kingdom to start utilising a PExA 2.0 system in their research. The instrument is planned to be installed in October 2018. Dr. Salman Siddiqui, Professor of respiratory medicine and airways disease, University of Leicester: - The PExA matrix is a unique lung matrix derived from the liquid lining the surface of small airways. PExA can be utilised to study a range of inflammatory, non-

PExA recruit expert in the field of BiomarkerDiscovery

PExA AB (”PExA”) that develop and commercialise an instrument which enable researchers to collect biological material from lung in an non-invasive way to study respiratory diseases, announces the recruitment of Jörgen Östling (PhD), a senior life science researcher.  Jörgen will assume his new role as ‘Manager, Bio­chemical Analysis and Research’ by January 15, 2018.Jörgen Östling holds a PhD in microbiology and has extensive experience from proteomics and bioinformatics. He has worked more than 20 years within the pharma industry, whereof the last six years focusing on the identification

Advancements for PExA at ERS, the world’s largest respiratory congress

PExA AB (“PExA”) is proud to announce that the Company’s method received scientific interest at the world’s largest lung congress, ERS, in Milan, Italy, with 25,000 participants from 9 to 13 September, 2017. The researchers behind PExA interpreted the reported findings and the interest in the results among researchers in this field as a breakthrough for the method.Five important studies* based on PExA were presented at the congress, showcasing the potential of the method from different aspects. However, the most important news at the congress was that by means of a sensitive analysis method

PExA receives Horizon 2020 funding

The European Commission has selected PExAs project “BREATH: Biomarkers for Respiratory diseases detected in Exhaled Air through a new Technological instrument for research and Healthcare markets” for funding through the Research and Innovation Framework Program Horizon 2020.The European Commission has selected PExAs projects for funding of a Phase 1 feasibility study through the "SME (Small Medium Enterprises) Instrument" call within EU’s Research and Innovation Framework Program Horizon 2020. Each project receives 50.000 Euro to carry out a feasibility study and to prepare a Phase 2

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe